Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Revoked by the SEC: VRGE Viragen International, Inc
NAME/SYMBOL CHANGES
DL Date Date Old Symbol/Name New Symbol/Name
3/26/2002 3/27/2002 VERP** Viragen (Europe) Ltd VGNI Viragen International
DIVIDENDS
Record Date Symbol Company Name Dividend Type
VGNI Viragen International, Inc. Common Stock Reverse Split 1-40 R/S **
NAME/SYMBOL CHANGES
DL Date Date Old Symbol/Name New Symbol/Name
9/4/2007 9/5/2007 VGNI Viragen International, Inc. Common Stock VRGE Viragen International, Inc. New Common Stock
http://www.otcbb.com/asp/dailylist_detail.asp?mkt_ctg=ALL&d=09/04/2007
SYMBOL CHANGES
DL Date Date Old Symbol New Symbol/Name
10/16/2007 10/18/2007 VRGE VRGEE Viragen International, Inc. Common Stock
SECURITY ADDITIONS
DL Date Symbol Company Name Effective Date OATS Reportable Flag Comments
11/16/2007 VRGE Viragen International, Inc. Common Stock 11/19/2007 From BB (VRGEE)**
SECURITY DELETIONS
Dl Date Symbol Company Name Effective Date/Comments
8/25/2008 VRGE Viragen International, Inc. Common Stock 8/26/2008 12(j) Registration Revoked by SEC **
http://www.otcbb.com/asp/dailylist_search.asp?DirectSymbol=VRGE&OTCBB=ALL
Sold some more VGNI into the news this morning:
PLANTATION, Fla., May 8 /PRNewswire-FirstCall/ -- Viragen, Inc. (AMEX: 'VRA'; 'VRA.U'; 'VRA.WS') and Viragen International, Inc. (OTC BB: 'VGNI') today announced results from a sponsored in vitro study conducted at Umea University in Sweden, which found that Multiferon(R) (multi- subtype, human alpha interferon) suppressed development of resistant human melanoma clones to a far greater degree than recombinant alpha interferon. The study has been accepted for publication in AntiCancer Research, International Journal of Cancer Research and Treatment.
The study, conducted by Professor Erik Lundgren, Head of Research at the Department of Molecular Biology, Umea University, was designed to compare Multiferon(R) and Intron(R) A* (Interferon alpha-2b, recombinant) with respect to the abilities of each product to inhibit the development of interferon- resistant melanoma cells in vitro, in order to better understand the reason for melanoma treatment failures.
The Study:
Three human melanoma cell lines were grown at a range of different cell concentrations in the presence of graded doses of either Multiferon(R) or Intron(R) A. After four weeks, the number of melanoma cell colonies were assessed and their properties analyzed.
Results:
Long-term treatment with Multiferon(R) was found to result in substantially fewer interferon-resistant melanoma clones than treatment with Intron(R) A. When treated with the single-subtype, recombinant alpha interferon, not only were distinct colonies found, but scattered individual cells were also observed. In contrast, during short term treatment, there was no difference in potency between the two interferon types with respect to growth and survival.
Conclusion:
The results suggest that the mixture of six human alpha subtypes present in Multiferon(R) (a1 a2, a8, a10, a14, a21) provides distinct benefits versus other alpha interferon products in vitro with respect to reducing the number of resistant clones.
According to Professor Lundgren, 'It is widely known that melanoma cells often develop resistance to recombinant alpha interferon therapies. We observed dramatically different outcomes when comparing Multiferon(R) against Intron(R) A in human melanoma cell lines in vitro, with Multiferon(R) clearly suppressing resistance development far more efficiently than Intron(R) A after four weeks of treatment. One possibility is that multiple subtypes of alpha interferon in Multiferon(R) are working synergistically to eradicate resistant cell clones. If Multiferon(R) is indeed suppressing the development of resistant melanoma clones, this effect may have played a role in improving overall survival in melanoma patients in Viragen's previously reported Phase II/III melanoma trial, published last year in Acta Oncologica.'
In February 2006, Multiferon(R) was approved in Sweden for the first-line adjuvant treatment of high-risk malignant melanoma. Viragen is preparing to proceed with a European Union (EU) regulatory process for Multiferon(R), through a registration pathway called the Mutual Recognition Procedure (MRP). This procedure allows a single registration dossier to be filed for approval among a targeted group of EU countries via one application and review process.
* Intron(R) A is registered trademark of Schering-Plough Corporation
About Malignant Melanoma:
Skin cancer is the most common type of cancer, accounting for more than 50% of all cancers. Melanoma accounts for approximately 4% of skin cancer cases, but causes 79% of skin cancer deaths. The American Cancer Society estimates that in 2006 there were 62,190 new cases of melanoma in the United States and about 7,910 people died of this disease.
About Multiferon(R):
Alpha interferon is produced by the human immune system and helps improve the body's natural resistance to disease.
Multiferon(R) differs from single-subtype recombinant alpha interferon drug products in that it contains a unique mixture of multiple subtypes of human interferon (a1, a2, a8, a10, a14, a21). It is believed that each subtype, some of which are glycosylated, employs a specific biological activity, but more importantly, the subtypes act synergistically to elicit an overall effect.
For prescription information, please visit: http://www.Multiferon.com
About Viragen, Inc.:
With international operations in the U.S., Scotland and Sweden, we are a bio-pharmaceutical company engaged in the research, development, manufacture and commercialization of therapeutic proteins for the treatment of cancers and viral diseases. Our product portfolio includes: Multiferon(R) (multi- subtype, human alpha interferon) which is uniquely positioned in valuable niche indications, such as high-risk malignant melanoma, and other select cancers and infectious diseases; VG102, a novel monoclonal antibody that binds selectively to an antigen that is significantly over-expressed on nearly all malignant tumors; and VG106, a novel cytokine targeting difficult-to-treat cancers. We are also pioneering the development of The OVA(TM) System with the renowned Roslin Institute, creators of 'Dolly the Sheep', as a revolutionary manufacturing platform for the large-scale, efficient and economical production of human therapeutic proteins and antibodies, by expressing these products in the egg whites of transgenic hens.
For more information, please visit: http://www.Viragen.com
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as 'believes,' 'expects,' 'potential,' 'plans,' 'suggests,' 'may,' 'should,' 'could,' 'intends,' or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the success of third- party marketing efforts; our ability to retain third-party distributors; our ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
SOURCE Viragen, Inc.
Source: PR Newswire (May 8, 2007 - 6:12 AM EDT)
News by QuoteMedia
www.quotemedia.com
Good to finally see an OB use PR Newswire as 5-releases are showing up on DJN....
Temp'
So they'll receive 2mil up front on the Swedish Orphan International AB deal, and Swedish Orphan International will pay Viragen for Multiferon® at an agreed upon sales price, and, in addition, Viragen will receive double-digit royalties from Swedish Orphan International on their net sales.
Then a licensing agreement with Orphan Australia Proprietary Limited that grants exclusive rights to Orphan Australia to market, stated back in Dec of 06, estimated the agreement to be valued at approximately $10 - 15 million (USD) per year for us.
Is that correct? Seems things are going better than what the market realizes at this time.
Temp
I still have some VGNI & VRA...selling some VGNI today...GLTY
Interesting news, low float, agreements going back a few months with a host of countries...
In for .10cent and above...
SirTemp'
http://biz.yahoo.com/prnews/070418/clw093.html?.v=46
One of those where you put in some money and look once a year how it is doing.
VGNI & VRA may be two to keep on the watch list for bottoming action.
Viragen's Multiferon(R) Approved in Sweden for First-Line Adjuvant Treatment of Malignant Melanoma
2006-02-21 02:00 ET - News Release
Also News Release (U-VRA) VIRAGEN INC
PLANTATION, Fla., Feb. 21 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex: VRA) and its majority-owned subsidiary, Viragen International, Inc. (OTC Bulletin Board: VGNI), today announced that the Swedish Medical Products Agency (MPA) approved Multiferon(R) (multi-subtype, natural human alpha interferon) for the first-line adjuvant treatment of high-risk (Stages IIb- III) malignant melanoma following dacarbazine (DTIC) after surgical removal of tumors. Viragen will officially launch this new malignant melanoma indication this month.
"We have long been dedicated to the positioning of Multiferon(R) as a leading therapy for certain cancers, and this approval validates our many years of hard work devoted to providing new hope for patients for the treatment of malignant melanoma," stated Orjan Norberg, Managing Director of ViraNative AB, the Viragen subsidiary, which manufactures Multiferon(R) in Umea, Sweden. "We are extremely proud that long-term studies have supported the use of Multiferon(R) in this cancer indication, and that our product has been shown to provide significant survival benefits, while also being well tolerated."
Approval for Multiferon(R) in sequential combination with DTIC was granted based on clinical trial data that demonstrated a statistically significant advantage over untreated controls in terms of survival-without-distant- metastasis and overall survival.
The current approved therapy for high-risk malignant melanoma in Sweden may include recombinant alpha interferon, following resection, for up to 18 months, sometimes in a high-dose regimen. By comparison, two doses of dacarbazine followed by low-dose Multiferon(R) for six months represents a significant reduction in total treatment time and cost.
Viragen's President and CEO, Charles A. Rice, commented, "We will now collaborate with the MPA and EU regulatory authorities to initiate the process for seeking broader European approvals through the Mutual Recognition Procedure. As we adapt our marketing activities in Sweden to immediately generate new sales of Multiferon(R), we will also provide support to our global license partners to expand this approval of Multiferon(R) in our international markets. In coordination with our expert Melanoma Advisory Board, we have initiated the process to conduct a post-marketing supporting clinical trial with Multiferon(R) on a pan-European basis. The trial is scheduled to include up to 1,000 patients in multiple centers across Europe and is expected to build additional clinical evidence of the value of Multiferon(R) in cancer therapy."
According to Cancer Research UK, Sweden reports the highest per capita incidence of malignant melanoma in men in Europe and the third highest incidence in women. (Based on 2002 Data)
Sequential DTIC/Multiferon(R) Therapy for High-Risk Malignant Melanoma:
Following resection, patients receive two doses of dacarbazine, followed by a 6-month regimen of Multiferon(R) at three doses per week (3 MIU) by subcutaneous injection.
About Malignant Melanoma:
Skin cancer is the most common type of cancer, accounting for more than 50% of all cancers. Melanoma accounts for approximately 4% of skin cancer cases, but causes 79% of skin cancer deaths. About 132,000 people worldwide are diagnosed with melanoma each year, and more than 37,000 die from the disease annually. According to Decision Resources, current pharmaceutical therapies are extremely toxic and ineffective in the majority of patients, and they predict that any emerging therapy that can bring modest improvements in overall survival and tolerability will revolutionize the treatment of malignant melanoma.
Decision Resources reports that the current worldwide melanoma therapeutics market is estimated at $437 million and is expected to exceed $1.1 billion worldwide by 2013. The European market is estimated to be approximately one-third of this total.
About Alpha Interferon:
The majority of marketed alpha interferons are single-subtype recombinant interferons. Therapy resistance is not unusual with recombinant interferons as a significant percentage of patients fail to respond or are unable to tolerate the adverse side effects commonly associated with high dosing, as is sometimes prescribed for melanoma treatment.
About Multiferon(R):
Multiferon(R) is a highly purified, multi-subtype, natural human alpha interferon. Marketed as "The natural choice(TM)", it is approved for sale in ten international markets (non-U.S.) for the first-line or rescue therapy for a broad range of infectious diseases and cancers. For more information, visit: http://www.Multiferon.com
About Viragen, Inc.:
With global operations in the U.S., Scotland and Sweden, Viragen is a biotechnology company engaged in the research, development, manufacture and commercialization of pharmaceutical proteins for the treatment of viral diseases and cancers. Our product portfolio includes: Multiferon(R) (multi- subtype, natural human alpha interferon) targeting a broad range of infectious and malignant diseases; and humanized monoclonal antibodies targeting specific antigens over-expressed on many types of cancers. We are also pioneering the development of Avian Transgenic Technology, with the renowned Roslin Institute, as a revolutionary manufacturing platform for the large-scale, efficient and economical production of human therapeutic proteins and antibodies.
For more information, please visit: http://www.Viragen.com
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as "expects," "potential," "suggests," "may," "should," "could," or similar expressions. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the Company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
SOURCE Viragen, Inc.
Followers
|
0
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
12
|
Created
|
02/28/06
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |